Navigation Links
ULURU Inc. Receives NYSE Amex Notice of Non-Compliance with Continued Listing Standards
Date:9/27/2011

ADDISON, Texas, Sept. 27, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today announced that the Company has received notice from the NYSE Amex (the "Exchange"), dated September 21, 2011, indicating that the Company is below the Exchange's stockholders' equity continued listing standards.  The Exchange Staff indicated that its review of the Company's Form 10-Q for the period year ended June 30, 2011, indicates that the Company does not meet the provisions of Section 1003(a)(iii) since the Company reported stockholders' equity of less than $6,000,000 at June 30, 2011 and has incurred losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2010.

The Company was afforded the opportunity to submit a plan of compliance to the Exchange by October 21, 2011, that demonstrates the Company's ability to regain compliance with Section 1003(a)(iii) of the Company Guide by March 21, 2013.  If the Company does not submit a plan of compliance, or if the plan is not accepted by the Exchange, the Company will be subject to delisting procedures as set forth in Section 1010 and part 12 of the Company Guide.

The Company believes it can provide the Exchange with a satisfactory plan by October 21, 2011, to show that it will be able to return to compliance with the minimum stockholder equity requirement.

While the notifications from NYSE Amex does not affect the current listing of the Company's common stock, the Company's failure to submit a plan of compliance with Section 1003(a)(iii) by October 21, 2011, or the failure of the NYSE Amex to accept any plan of compliance submitted, are likely to result in the Company no longer being listed on the NYSE Amex.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com.  For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's compliance with the continued listing standards of the NYSE Amex, the submission of a plan of compliance by ULURU and the acceptance of such plan of compliance by the NYSE Amex, the Company's ability to maintain its NYSE Amex listing, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Enters Into Strategic Financings of Up to $1.6 Million at a Premium to Current Share Price
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 20, 2011 and to Provide a Business Update
3. ULURU Inc. Announces Reverse Stock Split
4. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
5. ULURU Inc. Announces Voting Results of Reconvened Annual Meeting of Stockholders
6. ULURU Inc. Raises $140,000 in Convertible Debt Offering
7. ULURU Inc. Reports First Quarter 2011 Financial Results
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2011 and to Provide a Business Update
9. ULURU Inc. Announces the Filing of a 510(k) Application for Altrazeal® Collagen
10. ULURU Inc. Announces Going Concern Qualification
11. ULURU Inc. Announces Commercial Exhibit and Scientific Presentations at the SAWC/WHS National Wound Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)...  While nearly three-quarters of Americans (71%) are aware ... health, only about half report taking any steps to ... a new survey announced today by Hologic (Nasdaq: ... Osteoporosis Month, Hologic is raising awareness of this major ... Americans. Osteoporosis is a disease that causes ...
(Date:5/2/2016)... May 2, 2016 The ... USD 11.1 billion by 2024, according to a ... Major drivers of the sonography market include expanding ... government recommendations for periodic ultrasound screenings of the ... http://photos.prnewswire.com/prnh/20150105/723757 ) High Intensity ...
Breaking Medicine Technology:
(Date:5/2/2016)... CHICAGO (PRWEB) , ... May 02, 2016 , ... ... comprehensive treatment for eating, mood and anxiety disorders, has rebranded its eating disorder program ... a new residential eating disorder treatment facility on May 16. , To celebrate, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The National Resident Matching Program® ... Match® (“the Match”), the system through which U.S. and international medical school students ... positions were placed in the 2016 Match, and 29,572 were filled when the ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... Vegas, NV (PRWEB) , ... May 02, 2016 ... ... Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that ... determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... prescription medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering drugs, may cause cognitive ... Detox Center —a leading Florida-based drug treatment facility—advises patients to research the ...
Breaking Medicine News(10 mins):